Researchers at Stanford Medicine have developed a universal nasal spray vaccine that protects against a wide range of respiratory infections, including COVID-19, influenza, and bacterial pneumonia. Unlike traditional vaccines that target specific viruses, this approach reprograms innate immune cells in the lungs to provide broad protection within hours of infection.
In the study published in the journal Science, vaccinated mice survived infections from SARS-CoV-2, Staphylococcus aureus, and common allergens like house dust mites with clear lungs, while unvaccinated mice suffered severe inflammation and death. Protection lasted at least three months after a simple nasal drop.
Lead researcher Bali Pulendran estimates a human version could be available in five to seven years with sufficient funding. The breakthrough represents a potential paradigm shift in fighting respiratory diseases — moving from chasing individual viruses to training the body's frontline defenses to handle whatever comes next.
